Ha habido 50 transacciones internas recientes registradas para Cyclacel Pharmaceuticals, Inc. (CYCC), incluyendo 31 compras y 2 ventas. El total de compras internas fue valorado en $2.69M y el total de ventas internas en $42.86.
Internos destacados con actividad reciente incluyen Suria Sukses Engineering Sdn Bhd, Tan Kok Hui, Ho Jien Shiung. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — CYCC
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-04-29 |
Suria Sukses Engineering Sdn Bhd |
10 Percent Owner |
Desconocido |
- |
- |
- |
250,000 |
| 2025-04-29 |
Tan Kok Hui |
10 Percent Owner |
Desconocido |
- |
- |
- |
250,000 |
| 2025-04-29 |
Ho Jien Shiung |
10 Percent Owner |
Desconocido |
- |
- |
- |
250,000 |
| 2025-04-29 |
Ho Kee Wee |
10 Percent Owner |
Desconocido |
- |
- |
- |
250,000 |
| 2025-04-29 |
Tan Kok Hui |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-04-29 |
Suria Sukses Engineering Sdn Bhd |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-04-29 |
Ho Jien Shiung |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-04-29 |
Ho Kee Wee |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-04-02 |
Nair Krishnan Satis Waran |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-04-02 |
Laurduraj Inigo Angel |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-26 |
Natan David |
Director |
Concesión de RSU |
700,000 |
$0.33 |
$231K |
700,000 |
| 2025-02-26 |
Kiu Cu Seng |
CFO and Secretary |
Desconocido |
- |
- |
- |
- |
| 2025-02-26 |
Doris Wong Sing Ee |
10 Percent Owner, Officer: Chief Executive Officer |
Desconocido |
- |
- |
- |
194,628,820 |
| 2025-02-26 |
Chong Kwang Fock |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-26 |
Lazar David E. |
10 Percent Owner, Officer: Interim CEO |
Ejercicio de Opciones (Venta) |
1,000,000 |
- |
- |
- |
| 2025-02-26 |
Ben-tzvi Avraham |
Director |
Concesión de RSU |
700,000 |
$0.33 |
$231K |
700,000 |
| 2025-02-06 |
Lazar David E. |
10 Percent Owner, Officer: Interim CEO |
Concesión de RSU |
2,100,000 |
- |
- |
2,100,000 |
| 2025-01-05 |
Ben-tzvi Avraham |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-01-02 |
Natan David |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-01-02 |
Natan David |
Director |
Concesión de RSU |
100,000 |
- |
- |
100,000 |
| 2025-01-02 |
Lazar David E. |
Chief Executive Officer |
Desconocido |
2,650,000 |
- |
- |
- |
| 2024-01-29 |
Schwartz Brian |
Interim Chief Medical Officer |
Concesión de RSU |
12,500 |
$2.28 |
$28.5K |
12,500 |
| 2023-12-21 |
Rombotis Spiro George |
President and CEO |
Compra Informativa |
6,070 |
$3.19 |
$19.36K |
6,070 |
| 2023-12-21 |
Mcbarron Paul |
See Remarks |
Compra Informativa |
1,886 |
$3.19 |
$6.02K |
1,886 |
| 2023-06-30 |
Barker Sam L |
Director |
Concesión de RSU |
21,219 |
- |
- |
40,415 |
| 2023-06-30 |
Henney Christopher S |
Director |
Concesión de RSU |
21,219 |
- |
- |
39,415 |
| 2023-06-30 |
Rombotis Spiro George |
President and CEO |
Concesión de RSU |
110,000 |
$0.59 |
$64.8K |
110,000 |
| 2023-06-30 |
Mcbarron Paul |
See Remarks |
Concesión de RSU |
70,200 |
$0.59 |
$41.35K |
70,200 |
| 2023-06-30 |
Schwartz Brian |
Director |
Concesión de RSU |
21,219 |
- |
- |
40,602 |
| 2023-06-30 |
Spiegel Robert J. |
Director |
Concesión de RSU |
21,219 |
- |
- |
39,415 |
| 2023-06-30 |
Walker Karin L |
Director |
Concesión de RSU |
21,219 |
- |
- |
40,602 |
| 2023-06-30 |
Kirschbaum Mark |
Chief Medical Officer |
Concesión de RSU |
70,200 |
$0.59 |
$41.35K |
70,200 |
| 2023-06-30 |
Ferguson Kenneth M. |
Director |
Concesión de RSU |
42,438 |
$0.59 |
$25K |
42,438 |
| 2023-01-31 |
Rombotis Spiro George |
President and CEO |
Concesión de RSU |
57,600 |
- |
- |
62,588 |
| 2023-01-31 |
Mcbarron Paul |
See Remarks |
Concesión de RSU |
31,200 |
- |
- |
31,492 |
| 2023-01-31 |
Kirschbaum Mark |
Chief Medical Officer |
Concesión de RSU |
31,200 |
- |
- |
31,200 |
| 2022-06-14 |
Barker Sam L |
Director |
Concesión de RSU |
15,822 |
- |
- |
19,196 |
| 2022-06-14 |
Henney Christopher S |
Director |
Concesión de RSU |
15,822 |
- |
- |
18,196 |
| 2022-06-14 |
Schwartz Brian |
Director |
Concesión de RSU |
15,822 |
- |
- |
19,383 |
| 2022-06-14 |
Sems Lloyd |
Director |
Concesión de RSU |
15,822 |
- |
- |
18,196 |
| 2022-06-14 |
Spiegel Robert J. |
Director |
Concesión de RSU |
31,645 |
- |
- |
31,645 |
| 2022-06-14 |
Walker Karin L |
Director |
Concesión de RSU |
31,645 |
- |
- |
31,645 |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
Desconocido |
- |
- |
- |
- |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
Concesión de RSU |
27,733 |
- |
- |
27,733 |
| 2022-06-14 |
Ferguson Kenneth M. |
Director |
Concesión de RSU |
23,733 |
- |
- |
23,733 |
| 2021-12-13 |
Rombotis Spiro George |
President and CEO |
Concesión de RSU |
190,000 |
$3.45 |
$655.5K |
190,000 |
| 2021-12-13 |
Mcbarron Paul |
See Remarks |
Concesión de RSU |
100,000 |
$3.45 |
$345K |
100,000 |
| 2021-12-13 |
Kirschbaum Mark |
Chief Medical Officer |
Concesión de RSU |
100,000 |
$3.45 |
$345K |
100,000 |
| 2021-12-13 |
Rombotis Spiro George |
President and CEO |
Concesión de RSU |
190,000 |
$3.45 |
$655.5K |
190,000 |
| 2021-11-30 |
Barker Sam L |
Director |
Venta Informativa |
12 |
$3.57 |
$42.86 |
3,374 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento